January 31, 2025 expert reaction to NICE final draft guidance on exagamglogene autotemcel (exa-cel) for severe sickle cell disease . Scientists comment on final draft guidance fro ...

Justin Barbosa, GM and Vice President of TriLink Discovery, added “By integrating Molecular Assemblies technology into ...

A GROUNDBREAKING genetic treatment with the potential to cure sickle cell disease will be rolled out on the NHS. The one-off ...

Then Crispr came along—the elegant enzymatic ... pain is now being delivered to sickle cell patients, albeit at very high cost. For progeria and thousands of other genetic diseases, there ...

The market cap of Editas, however, would indicate that the value of this IP may not be all that high ... it would cost at least $150 million or so to make this purchase. While CRISPR could easily ...

CRISPR Therapeutics AG (NASDAQ ... diluting existing shareholders. Moreover, the high costs associated with gene therapy production and the complex manufacturing process could further pressure ...

This edit results in the production of high levels of fetal hemoglobin (HbF ... and commercialization of CASGEVY and splits program costs and profits worldwide 60/40 with CRISPR Therapeutics. Vertex ...

Well, Intellia was unable to evade these headwinds and announced they decided to lay off 27% of their staff and halt the development of one of their CRISPR ... timelines, high costs, and a murky ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $51.92, a high estimate ... on the development of Crispr/Cas9-based therapeutics.